A Ray of Hope for Vision: Lecheng Debuts Raxone, the First Authorized Treatment for LHON in China

In my tenure at Lecheng, each milestone in our mission to bridge global medical gaps carries its own weight. Yet the recent authorization of Raxone (idebenone 150mg) for clinical use here resonates with a particularly profound sense of purpose. This is not merely about adding another drug to our formulary; it is about offering a tangible, evidence-based intervention for a condition where therapeutic silence was the norm for over a century. For patients and families confronting Leber’s Hereditary Optic Neuropathy (LHON), a diagnosis often synonymous with sudden, irreversible vision loss, this arrival signifies the first glimmer of a scientifically validated treatment pathway on Chinese soil.

Raxone is the brand name for a specific, high-dose (150mg) tablet formulation of idebenone. It is a synthetic analog of coenzyme Q10, a vital component of the mitochondrial electron transport chain—the cellular machinery responsible for generating over 90% of the body’s energy (ATP). Idebenone is designed to provide superior antioxidant properties and to remain functional even in oxygen-deficient environments, a critical feature in dysfunctional cells.

Its primary and landmark therapeutic action is to serve as an electron carrier and a potent antioxidant within mitochondria. In the context of LHON, where specific genetic mutations cripple complex I of the respiratory chain, Raxone serves a dual purpose. First, it can partially bypass the defective complex I, shuttling electrons directly to complex III, thereby helping to restore essential ATP production. Second, and perhaps equally crucial, it neutralizes the excessive reactive oxygen species (ROS) released by these malfunctioning mitochondria, which are known to directly damage and ultimately trigger the death of retinal ganglion cells—the very cells whose axons form the optic nerve.

Leber’s Hereditary Optic Neuropathy is a prototypical mitochondrial disease. It is caused by specific point mutations in mitochondrial DNA (mtDNA), most commonly the m.11778G>A (ND4), m.3460G>A (ND1), and m.14484T>C (ND6) mutations. Unlike nuclear DNA, mtDNA is inherited exclusively from the mother, explaining the matrilineal inheritance pattern of LHON. However, penetrance is incomplete and influenced by modifying factors, meaning that not all carriers of the mutation develop the disease—a complexity that has long puzzled clinicians.

The clinical hallmark is the acute or subacute painless loss of central vision, typically beginning in one eye and involving the second eye within weeks or months. It predominantly affects young males in their second and third decades of life, though it can strike anyone. The global prevalence is estimated at approximately 1 in 30,000 to 50,000 individuals, translating to tens of thousands of patients worldwide. In China, with its large population, the absolute number of affected individuals is significant, yet for decades their therapeutic options were confined to supportive visual aids and psychosocial care, with no treatment available to alter the disease’s biological course.

The approval of Raxone was based on the landmark RHODOS (Rescue of Hereditary Optic Disease Outpatient Study) clinical trial and supported by extensive real-world evidence from its use in Europe since 2015. The pivotal data reveal a therapy that, while not a “cure,” represents a fundamental shift from passive observation to active intervention.

The Lecheng Pathway: From European Landmark to Chinese Reality

Raxone’s journey to Lecheng underscores a deliberate and necessary model for accessing ultra-orphan drugs. It received its first marketing authorization for LHON from the European Medicines Agency (EMA) in 2015 under exceptional circumstances—a recognition of both its promise and the dire unmet need. This was followed by approvals in other markets, including Switzerland and Canada. For years, it remained the only approved therapy for LHON worldwide. Lecheng’s special regulatory framework, designed precisely for such scenarios, has now enabled its supervised clinical use here. This move provides a legitimate, controlled, and expert-guided avenue for eligible Chinese patients and international medical travelers to access a treatment that could meaningfully alter their visual prognosis, years before a potential broader national approval.

The designation of Raxone as the global first and only authorized LHON treatment is not merely a commercial claim; it is a testament to the immense scientific and regulatory challenges inherent in developing therapies for rare mitochondrial diseases. Its approval broke a 150-year therapeutic void following the disease’s description. This status stems from several factors: the clear demonstration of a treatment effect in robust, placebo-controlled trials; the establishment of a favorable risk-benefit profile for a chronic, progressive condition; and the validation of its novel mitochondrial-targeting mechanism. While other therapeutic avenues (such as gene therapy for specific mutations) are under intensive investigation and hold considerable promise for the future, Raxone remains, as of today, the sole pharmacotherapy with broad regulatory approval across multiple regions, applicable to the most common LHON mutations. Its arrival at Lecheng thus marks the closing of a critical access gap for patients in this region.